UK chemicals and paint company Imperial Chemistry Industries has rejected a 600 pence a share, or L7.2 billion ($14.2 billion), cash offer from Dutch drug and chemical group Akzo Nobel. ICI said, according to various press reports, the offer "significantly undervalues the company," adding that any future offers should be above the 700 pence per share mark. John McAdam, ICI's chief executive, told shareholders that the firm planned to go on investing in both organic and acquisition-led expansion. In a press release, Akzo Nobel said that it believed that ICI would have been an attractive addition to its coatings and chemicals business following the decision to sell Organon (Marketletter February 26).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze